Objective: The intent of this study was to determine the efficacy and tolerance of single-dose oral azithromycin in the treatment of pregnant women with endocervical chlamydial carriage. 
hlamydia trachomatis carriage in pregnancy poses concerns for the patient, her unborn child, and her sexual partner. Erythromycin is now recommended, but it is associated with significant gastrointestinal side eff'ects. 2'3 Noncompliance is common, occurring in nearly 40% of patients. 4 A new drug, azithromycin, in a single 1-g dose, has been approved for the treatment of chlamydial cervicitis in nonpregnant individuals. A small prospective study in pregnant women showed that azithromycin was associated with cure rates similar to those of erythromycin but was significantly better tolerated. 5 We elected to use azithromycin preferentially because of potential enhanced compliance, reduced side effects, and excellent cure rate. The only alternate drug freely available was erythromycin. Presented is our experience with azithromycin's efficacy and tolerance in over 100 pregnant patients followed in our practice.
SUBJECTS AND METHODS
The patient population attended a community-based prenatal and family planning clinic adjacent to 2 low-income housing projects between January 1, 1993, and December 31, 1994. Surveillance data previously identified ch!amydial cervicitis as being present in greater that 20% of the patients attending this clinic. 6 The patients included in this report were identified by an audit of all clinic records. Only the patients with follow-up information about side effects were included. Five 9 The side effects, which did not vary substantially from those previously reported, were less common than those reported with erythromycin use in pregnancy.
2 Single-dose treatment, which is both effective and well tolerated, holds great promise for patients who may already be experiencing nausea while pregnant or for patients who maybe noncompliant with antibiotics. Noncompliance occurs more often among younger patients and those experiencing side effects.
Reinfection was a frequent occurrence in our study. Appropriate follow-up studies for chlamydia appear warranted in our population. Twenty-two percent of the treated and "cured" patients who were retested demonstrated chlamydia carriage later in the same pregnancy. The population characteristics of our study patients, being primarily young Afro-Americans residing in an urban setting, are recognized risk factors for recurrent infections in women.
